The Seropositive Rheumatoid Arthritis Drug Market forecast predicts robust growth, driven primarily by the expanding use of advanced therapeutic classes, particularly biosimilars and oral targeted synthetic DMARDs. The forecast is strongly influenced by the patent expiration of several blockbuster biologics, which is paving the way for cost-effective biosimilars. While this will introduce price...